Relmada Therapeutics, Inc. (RLMD)
RLMD Stock Price Chart
Explore Relmada Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze RLMD price movements and trends.
RLMD Company Profile
Discover essential business fundamentals and corporate details for Relmada Therapeutics, Inc. (RLMD) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
20 Jun 2014
Employees
17.00
Website
https://www.relmada.comCEO
Sergio Traversa
Description
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
RLMD Financial Timeline
Browse a chronological timeline of Relmada Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.21.
Earnings released on 12 May 2026
EPS came in at -$0.22 falling short of the estimated -$0.18 by -22.22%.
Earnings released on 19 Mar 2026
EPS came in at -$0.27 falling short of the estimated -$0.14 by -92.86%.
Earnings released on 13 Nov 2025
EPS came in at -$0.30 falling short of the estimated -$0.04 by -650.00%.
Earnings released on 7 Aug 2025
EPS came in at -$0.30 falling short of the estimated -$0.25 by -20.00%.
Earnings released on 12 May 2025
EPS came in at -$0.58 falling short of the estimated -$0.31 by -87.10%.
Earnings released on 27 Mar 2025
EPS came in at -$0.62 surpassing the estimated -$0.70 by +11.43%.
Earnings released on 7 Nov 2024
EPS came in at -$0.72 falling short of the estimated -$0.65 by -10.77%.
Earnings released on 7 Aug 2024
EPS came in at -$0.59 surpassing the estimated -$0.83 by +28.92%.
Earnings released on 8 May 2024
EPS came in at -$0.72 surpassing the estimated -$0.90 by +20.00%.
Earnings released on 19 Mar 2024
EPS came in at -$0.84 surpassing the estimated -$0.88 by +4.55%.
Earnings released on 8 Nov 2023
EPS came in at -$0.73 surpassing the estimated -$0.95 by +23.16%.
Earnings released on 8 Aug 2023
EPS came in at -$0.84 surpassing the estimated -$0.92 by +8.70%.
Earnings released on 11 May 2023
EPS came in at -$0.87 surpassing the estimated -$0.88 by +1.14%.
Earnings released on 23 Mar 2023
EPS came in at -$1.26 surpassing the estimated -$1.33 by +5.26%.
Earnings released on 10 Nov 2022
EPS came in at -$1.31 surpassing the estimated -$1.40 by +6.43%.
Earnings released on 11 Aug 2022
EPS came in at -$1.33 falling short of the estimated -$1.30 by -2.31%.
Earnings released on 5 May 2022
EPS came in at -$1.40 falling short of the estimated -$1.21 by -15.70%.
Earnings released on 23 Mar 2022
EPS came in at -$1.80 falling short of the estimated -$1.60 by -12.50%.
Earnings released on 11 Nov 2021
EPS came in at -$2.44 falling short of the estimated -$1.62 by -50.62%.
Earnings released on 10 Aug 2021
EPS came in at -$1.56 falling short of the estimated -$1.47 by -6.12%.
RLMD Stock Performance
Access detailed RLMD performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
